ALMS logo

ALMS Alumis Inc.

NASDAQ · Biotechnology · Healthcare

$3.96
-0.37 (-8.55%)

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of…

Market Cap: $514.09Mwww.alumis.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
—
60d
60
1 mentions
—
90d
49
8 mentions
—
news: 8

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 1Sell 0Strong Sell 0
Avg price target$26.6+571.7%
Low $15Median $27High $37
Current Consensus

Revenue

$1.91M
$0.00$5.80M$11.59M$17.39M
Mar 2023Sep 2026

Analyst Estimates

FY2025
$-2.86
$-3.09–$-2.62
5 analysts
FY2026
$-3.27
$-3.36–$-3.13
6 analysts
FY2027
$-2.81
$-3.11–$-2.58
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Martin Babler
Sector
Healthcare
Industry
Biotechnology
Employees
238
Beta
-0.67
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-2.73
www.alumis.com